Reuters -- Celgene Corp (CELG.O) said on Tuesday that its cancer drug Revlimid met the main goal of a late-stage trial of patients with multiple myeloma who had undergone a stem cell transplant.
Reuters -- Celgene Corp (CELG.O) said on Tuesday that its cancer drug Revlimid met the main goal of a late-stage trial of patients with multiple myeloma who had undergone a stem cell transplant.
